We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+10.01%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$3.38B
AUM Growth
–
Cap. Flow
+$3.36B
Cap. Flow
% of AUM
99.4%
Top 10 Holdings %
Top 10 Hldgs %
42.06%
Holding
56
New
56
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$186M |
| 2 |
Incyte
INCY
|
+$167M |
| 3 |
Gilead Sciences
GILD
|
+$153M |
| 4 |
Viatris
VTRS
|
+$141M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$137M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vertex Pharmaceuticals
VRTX
$123B
| $202M | 5.98% |
+2,526,014
| New | +$186M |
|
|
2
Incyte
INCY
$23.4B
| $168M | 4.97% |
+7,641,357
| New | +$167M |
|
|
3
Gilead Sciences
GILD
$167B
| $150M | 4.44% |
+2,930,957
| New | +$153M |
|
|
4
Viatris
VTRS
$20.1B
| $147M | 4.34% |
+4,730,003
| New | +$141M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $142M | 4.2% |
+1,125,666
| New | +$127M |
|
|
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
| $134M | 3.95% |
+5,434,346
| New | +$137M |
|
7
Innoviva
INVA
$1.6B
| $122M | 3.61% |
+3,930,393
| New | +$105M |
|
8
Merck
MRK
$315B
| $120M | 3.54% |
+2,698,945
| New | +$121M |
|
9
Boston Scientific
BSX
$65.4B
| $119M | 3.53% |
+12,864,121
| New | +$109M |
|
10
Edwards Lifesciences
EW
$49.4B
| $118M | 3.49% |
+10,551,822
| New | +$125M |
|
|
ONXX
11
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| $118M | 3.48% |
+1,356,043
| New | +$125M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.5B
| $110M | 3.25% |
+1,973,064
| New | +$123M |
|
|
IMGN
13
DELISTED
Immunogen Inc
IMGN
| $106M | 3.15% |
+6,418,984
| New | +$104M |
|
14
Illumina
ILMN
$28.2B
| $100M | 2.96% |
+1,375,864
| New | +$88.1M |
|
|
CELG
15
DELISTED
Celgene Corp
CELG
| $92.9M | 2.75% |
+1,587,872
| New | +$95.6M |
|
|
ARIA
16
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $92.6M | 2.74% |
+5,292,682
| New | +$93.8M |
|
17
Amgen
AMGN
$198B
| $88.8M | 2.63% |
+900,519
| New | +$93.4M |
|
18
Align Technology
ALGN
$12.7B
| $88.4M | 2.61% |
+2,385,406
| New | +$82.2M |
|
|
AGN
19
DELISTED
Allergan Inc
AGN
| $88.3M | 2.61% |
+1,047,777
| New | +$109M |
|
20
Perrigo
PRGO
$1.48B
| $71.8M | 2.12% |
+593,725
| New | +$70.4M |
|
21
Eli Lilly
LLY
$1.05T
| $63.3M | 1.87% |
+1,288,250
| New | +$70.1M |
|
22
Regeneron Pharmaceuticals
REGN
$70.9B
| $61.8M | 1.83% |
+274,666
| New | +$64M |
|
23
Biogen
BIIB
$30.4B
| $61M | 1.8% |
+283,300
| New | +$60.5M |
|
|
HTWR
24
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $57.6M | 1.7% |
+605,947
| New | +$55.1M |
|
|
VAR
25
DELISTED
Varian Medical Systems, Inc.
VAR
| $57M | 1.68% |
+962,875
| New | +$57.7M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Sectoral Asset Management, which disclosed 56 positions worth $3.38B. Its ten largest holdings account for 42% of the portfolio.
Its largest position is Vertex Pharmaceuticals: 2,526,014 shares worth $202M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets.
- Sectoral Asset Management's largest Q2 2013 buy was Vertex Pharmaceuticals: 2,526,014 shares worth $202M.
- Sectoral Asset Management's ten largest holdings make up 42% of its $3.38B portfolio in Q2 2013.
- Sectoral Asset Management disclosed 56 positions in Q2 2013, its first 13F filing on record.
Based on Sectoral Asset Management's 13F filing for Q2 2013, filed 12 Aug 2013.